Patients with hemophilia A are defined as "severe" if they present <0.01 IU mL-1 of clotting factor VIII (FVIII) activity endogenously (i.e. in absence of FVIII concentrate administration). However, an exact measurement of baseline FVIII is often impossible in such patients as the lower limit of quantification for most FVIII assays is around 0.01 IU mL-1, forcing assumptions to be made regarding endogenous circulating level.

The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A

Iorio, A
;
2018

Abstract

Patients with hemophilia A are defined as "severe" if they present <0.01 IU mL-1 of clotting factor VIII (FVIII) activity endogenously (i.e. in absence of FVIII concentrate administration). However, an exact measurement of baseline FVIII is often impossible in such patients as the lower limit of quantification for most FVIII assays is around 0.01 IU mL-1, forcing assumptions to be made regarding endogenous circulating level.
2018
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1448389
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact